Hydro-Gear Limited Partnership

Merck Sharp + Dohme Corp.

Polaris Industries Inc.

Idenix Pharmaceuticals, Inc.

Merck + Co., Inc.

Merch Sharp & Dohme Ltd

Hydro-Gear

John D Schreier

Paul J Coleman

Raymond M Hauser

Christopher D Cox

Izzat Tiedje Raheem

Michael Lee Bennett

Jeffrey David Bennett

Lonnie E Holder

Michael J Breslin

Herb M Poplawski

Louis James Brady

Stephen L Nelson

Anthony J Roecker

Timothy John Hartingh

Ray M Hauser

Jean-Laurent Paparin

Sean E Sherrod

Daryl Smothers

Thomas J Langenfeld

Mark E Fraley

John S Wai

Thomas H Graham

Lihong Hu

Xuanjia Peng

George D Hartman

Scott W Keller

Sherman Tim Waddell

David Dukhan

Jeffrey M Bergman

Mark W Embrey

Manuel De Lera Ruiz

Petr Vachal

William Burt Rodriguez

Daniel S Weber

Ryan K Lovold

Todd Horton

Matthew J Hansen

Benjamin J Dieter

Ron Sporrer

Alan S Olson

Steve L Nelson

Ronald J Sporrer

Harry Pongo

Nathan D Dahl

Thomas D Wiley

Ralph A McClelland

Scott E McKinster

Broc A Flores

John T Sisko

Houcine Rahali

David B Whitman

Zhiqiang Guo

Swati P Mercer

Ming Wang

Daniel E Erickson

Georgia B McGaughey

Roy A Sunsdahl

Daniel Da Costa

Wenlang Fu

Ron R Danielson

Aurélien Salanson

Michael Houser

Ning Qi

Herb M Poplawsli

Juan Pedro Roberto A Ooink

Daniel Scott Weber

Broc Flores

Georgia B Mcgaughey

Nathan Dale Dahl

Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral benzyl-amine phosphodiamide compounds

An all-terrain vehicle including a frame having longitudinally-spaced ends defining a first longitudinal axis, and an engine supported by the frame. The engine includes a crankshaft defining a second longitudinal axis substantially parallel to the first longitudinal axis.

All terrain vehicle

Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral phosphodiamide prodrugs of tenofovir

Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral aryl-amide phosphodiamide compounds

Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral oxime phosphoramide compounds

The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject. 

Spirocyclic heterocyclic compounds useful as HIV integrase inhibitors

The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein R-R, A, X and n are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject. 

Fused tricyclic heterocyclic compounds as HIV integrase inhibitors

The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pyrazolopyrimidine PDE 10 inhibitors

A vehicle is described having a transmission driven through a propulsion unit such as an engine, and through a CVT. The transmission is comprised of an input shaft and an output shaft which are coaxially disposed. An idler shaft is driven by the input shaft, and the idler shaft drives the output shaft, through selected gear sets, to provide different gear ratios or drive directions. The CVT also has a fan on the driven side which feeds air through the CVT for cooling. The CVT comprises a drive side clutch and a driven side clutch with the output shaft of the extending through the CVT driven clutch.

Vehicle and transmission for a vehicle

The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

2,5-disubstituted piperidine orexin receptor antagonists

The present invention is directed to pyridazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Pyridazine carboxamide orexin receptor antagonists

The present invention is directed to amino tetrahydro-pyridopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Amino tetrahydro-pyridopyrimidine PDE10 inhibitors

Growing community of inventors

Lindstrom, MN, United States of America

John D Schreier